ANA Therapeutics and Quotient Sciences to Collaborate on Potential COVID-19 Treatment
ANA will use Quotient’s formulation and manufacturing knowledge to develop and supply the drug product for clinical trials by the third quarter of 2020.
ANA Therapeutics, a biotech startup, and Quotient Sciences, a drug development and manufacturing solutions company, announced on August 11, 2020 that they are collaborating on the manufacturing of ANA Therapeutics’ drug candidate, ANA001 (niclosamide capsules), for the potential treatment of COVID-19.
Under the terms of the agreement, Quotient will scale up the capsule formulation, and characterize and optimize the manufacturing process of the drug candidate through to clinical trials using its facility in Garnet Valley, PA, according to a Quotient press release. ANA will use Quotient’s formulation and manufacturing knowledge to develop and supply the drug product for clinical trials by the third quarter of 2020.
“We have selected Quotient Sciences as our development and manufacturing partner and our plan is simple,” said Andrew Bartynski, chief operation officer, ANA Therapeutics, in the press release. “Niclosamide has the potential to be an effective antiviral agent to combat COVID-19, and our top goal is to complete a clinical trial to determine its efficacy in treating patients with COVID-19. Quotient’s speed and agility will play a key role in reaching that important milestone.”
“We are proud to partner with ANA Therapeutics in their pursuit of a treatment to fight this coronavirus pandemic,” added Mark Egerton, PhD, CEO of Quotient Sciences, in the press release. “Our experience and flexible manufacturing approaches will enable ANA Therapeutics to initiate clinical testing in an accelerated timeframe.”
Source: Quotient
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
